Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

ibitors

Nefazodone

Gemfibrozil Do not exceed 20 mg lovastatin daily

Other fibrates

Lipid-lowering doses

(Greater Than or Equal To 1 g/day)

of niacin

Cyclosporine

Danazol

Amiodarone Do not exceed 40 mg lovastatin daily

Verapamil

Grapefruit juice Avoid large quantities of grapefruit

juice (>1 quart daily)

Liver Dysfunction

Persistent increases (to more than 3 times the upper limit of normal) in serum transaminases occurred in 1.9% of adult patients who received lovastatin for at least one year in early clinical trials (see ADVERSE REACTIONS). When the drug was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases usually appeared 3 to 12 months after the start of therapy with lovastatin, and were not associated with jaundice or other clinical signs or symptoms. There was no evidence of hypersensitivity. In the EXCEL study (see CLINICAL PHARMACOLOGY, Clinical Studies), the incidence of persistent increases in serum transaminases over 48 weeks was 0.1% for placebo, 0.1% at 20 mg/day, 0.9% at 40 mg/day, and 1.5% at 80 mg/day in patients on lovastatin. However, in post- marketing experience with MEVACOR, symptomatic liver disease has been reported rarely at all dosages (see ADVERSE REACTIONS).

In AFCAPS/TexCAPS, the number of participants with consecutive elevations of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (> 3 times the upper limit of normal), over a median of 5.1 years of follow- up, was not significantly different between the MEVACOR and placebo groups (18 [0.6%] vs. 11 [0.3%]). The starting dose of MEVACOR was 20 mg/day; 50% of the MEVACOR treated participants were titrated to 40 mg/day at Week 18. Of the 18 participants on MEVACOR with consecutive elevati
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in it at age ... every year. Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” ... scary unknown out of menopause. , Myth #1: Menopause only affects old ladies. ...
(Date:8/4/2015)... ... , ... School is almost back in session. Parents and children are enjoying ... scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile Dental) reminds parents ... In fact, the dentist recently updated the practice’s surgical suite to prepare for nervous ...
(Date:8/4/2015)... ... 2015 , ... Many men are confused about the safety of testosterone replacement ... as a voice of authority for men seeking accurate information about testosterone. , ... and expertise in the safe and effective treatment of low testosterone. In recent years, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye ... entering kindergarten. All required immunizations are covered for members under the Healthchek program ... who aren’t caught up with their immunizations may not be allowed to attend ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... specialist makes a difference, study finds , WEDNESDAY, Aug. 22 ... to see the doctor who diagnoses their melanoma, the more ... -- skin cancer at the time of diagnosis, a new ... poorer patients getting diagnosed with thicker melanomas, the researchers said. ...
... the brain, study suggests , , WEDNESDAY, Aug. 22 (HealthDay ... frightening, traumatic memories go so deep and linger so ... rats shows that a powerful neurochemical called norepinephrine is ... but it also "imprints" an emotional fear tagged to ...
... weak or unsubstantiated, review finds , TUESDAY, Aug. 21 (HealthDay ... disease often lack proper documentation or validation, experts report in ... American Medical Association . , A team of researchers in ... They found that 286 (66.2 percent) of these claims were ...
... Fried, baked food compound poses no threat, major study finds ... be little or no link between breast cancer and acrylamide, ... to the largest epidemiological study on the subject conducted to ... acrylamide in the diet does not appear to be an ...
... in Taiwan has shown that an 800-year-old formula, Four-Agents ... pain after three cycles of treatment; however, a beneficial ... dosage regimen and treatment length used in this study ... published in the August 15 issue of the online, ...
... A computer bug infected Web gamers, with ominous results, ... Online role-playing games could provide insight into how infectious ... the real world, American researchers report. , A programming ... ("corrupted blood") among virtual characters in the popular online ...
Cached Medicine News:Health News:Melanoma Diagnosis Often Delayed for Rural Poor 2Health News:Study Probes Roots of Fearful Memories 2Health News:Gene Studies of Male-Female Differences Often Flawed 2Health News:Acrylamide Won't Raise Breast Cancer Risk 2Health News:Acrylamide Won't Raise Breast Cancer Risk 3Health News:Acrylamide Won't Raise Breast Cancer Risk 4Health News:Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea? 2Health News:Online 'Epidemic' Gives Clues to Bird Flu Spread 2
(Date:8/4/2015)... 4, 2015  Eli Lilly and Company (NYSE: ... Diego (UCSD) of its intent to end its contract ... Treatment in Asymptomatic Alzheimer,s disease (A4) study. The A4 ... the preclinical stage of Alzheimer,s disease in older individuals ... a PET scan, but do not show symptoms of ...
(Date:8/4/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... Sangamo,s executive vice president, research and development, will provide ... ® development programs and an overview of the ... 11, 2015, at the 2015 Wedbush Pacgrow Healthcare Conference. ... York, NY . The presentation will ...
(Date:8/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... second quarter ended June 30, 2015 and provided a ... eight XmAb® antibody candidates are in clinical testing, ... momentum of this pipeline of antibodies is a ...
Breaking Medicine Technology:Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 2Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 3Sangamo BioSciences Announces Presentation At The 2015 Wedbush Pacgrow Healthcare Conference 2Xencor Reports Second Quarter 2015 Financial and Operating Results 2Xencor Reports Second Quarter 2015 Financial and Operating Results 3Xencor Reports Second Quarter 2015 Financial and Operating Results 4Xencor Reports Second Quarter 2015 Financial and Operating Results 5Xencor Reports Second Quarter 2015 Financial and Operating Results 6Xencor Reports Second Quarter 2015 Financial and Operating Results 7Xencor Reports Second Quarter 2015 Financial and Operating Results 8Xencor Reports Second Quarter 2015 Financial and Operating Results 9
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... explanation of foldable intraocular lenses. The instrument ... placed under the implant and divides the ... helps support both halves of the lens ... in the anterior chamber is avoided. The ...
Medicine Products: